Navigation Links
Neurobiological Technologies, Inc. Reports Fourth Quarter and Fiscal Year-End Financial Results for 2007 Announces 1-for-7 Reverse Stock Split
Date:9/14/2007

consisted of $5.1 million of royalty fees earned from the commercial sales of memantine by Merz and its marketing partners in the United States and certain European countries, $3.2 million from the sale of NTI's rights and assets related to XERECEPT to Celtic, and $4.0 million from the reimbursement of the direct expenses incurred for the services provided to Celtic.

Research and development expenses of $26.7 million in the year ended June 30, 2007 increased by $3.9 million compared to R&D expenses of $22.8 million in fiscal year 2006. During fiscal year 2007, $21.2 million of the R&D expenses were focused on Viprinex(TM), with the remaining $5.5 million on XERECEPT. The increase in research and development expenses resulted from an additional $5.2 million of expenses incurred for the Phase 3 clinical trials of Viprinex, which was partially offset by a decrease of $1.3 million of reimbursed expenses for the continuing Phase 3 clinical trials for XERECEPT.

The Company had no acquired in-process research and development expenses for the fiscal year ended June 30, 2007 compared to $11.5 million for the fiscal year ended June 30, 2006. The 2006 expenses represented the expensing of certain tangible and intangible assets related to the acquisition of Empire Pharmaceuticals from 2005.

General and administrative expenses totaled $6.5 million for the year ended June 30, 2007 compared to $6.0 million in fiscal year 2006. The increase in general and administrative expenses resulted primarily from increases of approximately $362,000 for compensation, $259,000 for consultants and $276,000 for audit fees, offset by a $243,000 decrease in legal fees.

Investment income for the fiscal year ended June 30, 2007 totaled approximately $494,000 compared to $399,000 in fiscal year 2006. The increase was due to higher average cash balances in fiscal 2007 and an increase in our average rate of return on our investment portfolio.

Gain on change in value of warr
'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... Japan , April 16, 2015  Center ... University and Takeda Pharmaceutical Company Limited (Takeda) announced ... clinical applications of induced pluripotent stem cells in ... disorders and cancer immunotherapy. The "Takeda-CiRA Joint Program ... expedite multiple research projects for drug discovery and ...
(Date:4/16/2015)... April 16, 2015 Proove Biosciences ... Buzz of BIO Contest for the 2015 BIO ... the 2015 BIO International Convention will take place June ... During the Buzz of BIO contest, industry leaders will ... present at the conference. The community voting period began ...
(Date:4/16/2015)... April 16, 2015 OncoTAb, ... Charlotte (UNC Charlotte) spin-out company, announced today the ... Ph.D., M.D., as Chief Operating Officer (COO). Cooper ... experience in developing clinical diagnostic and biotechnology platforms ... disease. , Cooper’s extensive career transcends the field ...
(Date:4/16/2015)... , April 16, 2015  RegeneRx Biopharmaceuticals, Inc. ... its U.S. joint venture with G-treeBNT (ReGenTree LLC) ... 3 clinical trial for the orphan disorder, neurotrophic ... for dry eye syndrome (DES) in the U.S.  ... drops, RGN-259/GBT201, this year.  Each of these eye ...
Breaking Biology Technology:CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 2CiRA and Takeda Enter 10-year Collaboration on iPS Cell Research 3Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 2Proove Bisociences to Participate in the Buzz of BIO at the 2015 BIO International Convention 3OncoTAb Names Dr. David L. Cooper as COO 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5
... China, Feb. 7 /Xinhua-PRNewswire-FirstCall/ -- Tianyin,Pharmaceutical, Inc., (OTC ... traditional Chinese medicine (TCM) based in Chengdu,China, today ... the Board of,Directors, will host a conference call ... results., The conference call will take place ...
... 7 Dilon Technologies, makers of,a gamma imaging system ... Moussa to the position of President and Chief Executive,Officer., ... the medical device industry,having held a number of senior ... a health care corporation he ran as,CEO for a ...
... 7 MedImmune today announced,that it has strengthened ... affairs with three key promotions and has also ... Kiener, D. Phil. has been appointed,to executive vice ... organization development, HR; and Eileen Valenta to vice ...
Cached Biology Technology:Tianyin Pharmaceutical, Inc. to Host 2008 Second Quarter Earnings Conference Call on Thursday, February 14, 2008 at 4:15 p.m. EST 2Newly Appointed Dilon Technologies President & CEO Robert G. Moussa Sees BSGI as ' ... Major Weapon in the Battle Against Cancer' 2MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio 2MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio 3MedImmune Strengthens Key Leadership Functions to Further Support Recently Expanded, Rapidly Advancing Product Portfolio 4
(Date:4/2/2015)... 2, 2015 Fingerprint Cards (FPC) ... FPC1025 from the distributor World Peace Industrial Group (WPI), ... 2015 although the major part of the shipments will ... used by smartphone manufacturers in China ... in the communicated revenue guidance of + 1 000 MSEK ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... forecast the Global Gesture Recognition market in Automotive Sector ... period 2013-2018. Gesture recognition is the ability ... gestures of an individual. Gesture recognition technology can be ...
(Date:3/24/2015)... March 24, 2015   Crossmatch ™, a ... announced that its U.are.U ® 4500 Fingerprint ... Goorin Bros . to achieve PCI compliance for ... access to the POS terminal, protecting the retailer ... data breaches. With one-third of ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 110 Million 2Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2
... for the first time a surprising and unexpected plasticity ... cells are made in early development. Scientists ... type of gene that controls cell fate by regulating ... stem and progenitor cells in blood forming tissues to ...
... (August 2, 2012) Autism Speaks, the world,s ... its expanded collaboration with Sigma Advanced Genetic Engineering ... develop the first rat models with modified autism ... autism research. Expansion of the collaboration follows ...
... in 10 children suffers from asthma but the potential ... known. Cincinnati-based researchers now report new evidence that exposure ... a direct link to asthma development during childhood. ... Penicillium variabileare typically found growing in water-damaged homes, putting ...
Cached Biology News:Embryonic blood vessels that make blood stem cells can also make beating heart muscles 2Embryonic blood vessels that make blood stem cells can also make beating heart muscles 3Autism Speaks and SAGE® Labs develop rat models for translational autism research 2Autism Speaks and SAGE® Labs develop rat models for translational autism research 3Infants exposed to specific molds have higher asthma risk 2
IHC Detection Kit (Broad Spectrum AEC)....
...
...
... to L1 Cell Adhesion Molecule ... in Xq28, is involved in three distinct ... of Sylvius); 2) MASA (mental retardation, aphasia, ... (spastic paraplegia). Immunogen: ...
Biology Products: